Kynurenic acid, a key L-tryptophan-derived metabolite, protects the heart from an ischemic damage.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
19
09
2022
accepted:
20
06
2023
medline:
28
8
2023
pubmed:
24
8
2023
entrez:
24
8
2023
Statut:
epublish
Résumé
Renal injury induces major changes in plasma and cardiac metabolites. Using a small- animal in vivo model, we sought to identify a key metabolite whose levels are significantly modified following an acute kidney injury (AKI) and to analyze whether this agent could offer cardiac protection once an ischemic event has occurred. Metabolomics profiling of cardiac lysates and plasma samples derived from rats that underwent AKI 1 or 7 days earlier by 5/6 nephrectomy versus sham-operated controls was performed. We detected 26 differential metabolites in both heart and plasma samples at the two selected time points, relative to sham. Out of which, kynurenic acid (kynurenate, KYNA) seemed most relevant. Interestingly, KYNA given at 10 mM concentration significantly rescued the viability of H9C2 cardiac myoblast cells grown under anoxic conditions and largely increased their mitochondrial content and activity as determined by flow cytometry and cell staining with MitoTracker dyes. Moreover, KYNA diluted in the drinking water of animals induced with an acute myocardial infarction, highly enhanced their cardiac recovery according to echocardiography and histopathology. KYNA may represent a key metabolite absorbed by the heart following AKI as part of a compensatory mechanism aiming at preserving the cardiac function. KYNA preserves the in vitro myocyte viability following exposure to anoxia in a mechanism that is mediated, at least in part, by protection of the cardiac mitochondria. A short-term administration of KYNA may be highly beneficial in the treatment of the acute phase of kidney disease in order to attenuate progression to reno-cardiac syndrom and to reduce the ischemic myocardial damage following an ischemic event.
Sections du résumé
BACKGROUND
Renal injury induces major changes in plasma and cardiac metabolites. Using a small- animal in vivo model, we sought to identify a key metabolite whose levels are significantly modified following an acute kidney injury (AKI) and to analyze whether this agent could offer cardiac protection once an ischemic event has occurred.
METHODS AND RESULTS
Metabolomics profiling of cardiac lysates and plasma samples derived from rats that underwent AKI 1 or 7 days earlier by 5/6 nephrectomy versus sham-operated controls was performed. We detected 26 differential metabolites in both heart and plasma samples at the two selected time points, relative to sham. Out of which, kynurenic acid (kynurenate, KYNA) seemed most relevant. Interestingly, KYNA given at 10 mM concentration significantly rescued the viability of H9C2 cardiac myoblast cells grown under anoxic conditions and largely increased their mitochondrial content and activity as determined by flow cytometry and cell staining with MitoTracker dyes. Moreover, KYNA diluted in the drinking water of animals induced with an acute myocardial infarction, highly enhanced their cardiac recovery according to echocardiography and histopathology.
CONCLUSION
KYNA may represent a key metabolite absorbed by the heart following AKI as part of a compensatory mechanism aiming at preserving the cardiac function. KYNA preserves the in vitro myocyte viability following exposure to anoxia in a mechanism that is mediated, at least in part, by protection of the cardiac mitochondria. A short-term administration of KYNA may be highly beneficial in the treatment of the acute phase of kidney disease in order to attenuate progression to reno-cardiac syndrom and to reduce the ischemic myocardial damage following an ischemic event.
Identifiants
pubmed: 37616231
doi: 10.1371/journal.pone.0275550
pii: PONE-D-22-25974
pmc: PMC10449225
doi:
Substances chimiques
Kynurenic Acid
H030S2S85J
Tryptophan
8DUH1N11BX
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0275550Informations de copyright
Copyright: © 2023 Bigelman et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
PLoS One. 2014 Dec 01;9(12):e113653
pubmed: 25436994
Arterioscler Thromb Vasc Biol. 2015 Feb;35(2):455-62
pubmed: 25524770
Int J Tryptophan Res. 2016 May 17;9:17-29
pubmed: 27226722
FASEB J. 1991 Aug;5(11):2516-22
pubmed: 1907934
Pharmacol Rep. 2014 Dec;66(6):1127-33
pubmed: 25443745
Neurotoxicol Teratol. 2011 Sep-Oct;33(5):538-47
pubmed: 21763768
New Phytol. 2016 Apr;210(1):88-96
pubmed: 26856244
Am J Physiol Heart Circ Physiol. 2018 Apr 1;314(4):H733-H752
pubmed: 29351456
Neuropharmacology. 2017 Jan;112(Pt B):373-388
pubmed: 26995730
Cardiovasc Res. 2014 Jan 1;101(1):69-77
pubmed: 24095869
Metabolites. 2019 Dec 19;10(1):
pubmed: 31861670
Heart Fail Clin. 2014 Apr;10(2):251-80
pubmed: 24656104
J Cardiovasc Pharmacol. 2020 Jun;75(6):556-563
pubmed: 32195756
Ren Fail. 2013;35(5):648-53
pubmed: 23650931
STAR Protoc. 2021 Apr 20;2(2):100466
pubmed: 33997804
J Am Soc Nephrol. 2015 Oct;26(10):2378-87
pubmed: 25644112
Naunyn Schmiedebergs Arch Pharmacol. 2020 Apr;393(4):673-679
pubmed: 31807837
Anesthesiology. 2012 May;116(5):1139-48
pubmed: 22415388
Heart Fail Rev. 2015 May;20(3):259-72
pubmed: 25344016
Clin Exp Pharmacol Physiol. 2006 Nov;33(11):1078-87
pubmed: 17042918
Molecules. 2021 May 11;26(10):
pubmed: 34064778
Kidney Int. 2019 Mar;95(3):590-610
pubmed: 30709662
Indian Heart J. 2017 Mar - Apr;69(2):255-265
pubmed: 28460776
J Am Soc Nephrol. 2006 May;17(5):1316-24
pubmed: 16597686
Am J Hypertens. 2018 Aug 3;31(9):1049-1058
pubmed: 29860395
Front Biosci (Landmark Ed). 2015 Jun 01;20(7):1116-43
pubmed: 25961549
Circ Res. 2004 Dec 10;95(12):1140-53
pubmed: 15591236
Cell Rep. 2021 Jan 5;34(1):108583
pubmed: 33406416
PLoS One. 2018 Jun 11;13(6):e0198196
pubmed: 29889834
PLoS One. 2017 May 8;12(5):e0177132
pubmed: 28481959
PLoS One. 2014 Aug 19;9(8):e105055
pubmed: 25136832
Eur J Clin Invest. 2003 Jul;33(7):550-4
pubmed: 12814390
Cytometry A. 2011 Jun;79(6):405-25
pubmed: 21595013
Science. 2022 Aug 5;377(6606):621-629
pubmed: 35926043
Biochem Biophys Res Commun. 2010 Feb 26;393(1):55-60
pubmed: 20100464
Kidney Int. 2002 Nov;62(5):1776-83
pubmed: 12371979
Plant Cell. 2011 Dec;23(12):4507-25
pubmed: 22180624
Cell Mol Life Sci. 2017 Aug;74(16):2899-2916
pubmed: 28314892
Int J Tryptophan Res. 2009;2:1-19
pubmed: 22084578
Circulation. 2022 Jun 14;145(24):1799-1802
pubmed: 35696459
Biomed Chromatogr. 2018 Apr;32(4):
pubmed: 29193181
J Biol Chem. 2006 Aug 4;281(31):22021-22028
pubmed: 16754668
Front Neurol. 2019 Jul 19;10:778
pubmed: 31379727
Mol Cell Endocrinol. 2020 Feb 5;501:110642
pubmed: 31759100
Toxins (Basel). 2020 Mar 05;12(3):
pubmed: 32150864
Mol Neurodegener. 2021 Feb 15;16(1):7
pubmed: 33588894
Pharmacology. 2001 Feb;62(2):119-23
pubmed: 11174083
Nat Rev Immunol. 2004 Oct;4(10):762-74
pubmed: 15459668
J Pharmacol Exp Ther. 2008 Jan;324(1):342-51
pubmed: 17940199
Life Sci. 2004 Sep 17;75(18):2181-92
pubmed: 15325844
Clin J Am Soc Nephrol. 2017 Nov 7;12(11):1787-1794
pubmed: 28971980
Ann Med. 2010;42(1):55-63
pubmed: 19941414
Circ Res. 2014 Jan 31;114(3):480-92
pubmed: 24281189
PLoS One. 2013 Nov 29;8(11):e82180
pubmed: 24312407
Adv Exp Med Biol. 1999;467:389-95
pubmed: 10721080
Am J Physiol Renal Physiol. 2000 Sep;279(3):F565-72
pubmed: 10966936
Nature. 2011 Jan 13;469(7329):221-5
pubmed: 21124315
EMBO Rep. 2012 Apr;13(4):378-85
pubmed: 22354088